Gisele Loth
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Gisele Loth has a total of 124 co-authors. Here are the top co-authors by number of shared publications:
- Carmem Bonfim
Duke University – Durham – Carolina do Norte – Estados Unidos
10 shared publications - Samantha Nichele
Bone Marrow Transplantation Unit, Federal University of Paraná, Curitiba, Brazil
4 shared publications - Ana Karine Vieira
Universidade Federal de Minas Gerais – Hospital das Clínicas – Belo Horizonte (MG), Brazil|Grupo Santa Casa de Belo Horizonte – Belo Horizonte (MG), Brazil
3 shared publications - Ricardo Pasquini
Hospital de Clínicas – Universidade Federal do Paraná / Hospital Nossa Senhora das Graças – Instituto Pasquini, Curitiba, PR
3 shared publications - Vaneuza Araújo Moreira Funke
Universidade Federal do Paraná – Hospital de Clínicas – Curitiba (PR), Brazil
3 shared publications - Adriana Koliski
Pediatric Intensive Care Unit, Complexo Hospital de Clínicas da Universidade Federal do Paraná, Brazil
2 shared publications
Latest Publications
- Open Access
- 22 January 2025
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 6 (1)
Hematopoietic cell transplantation in inborn errors of immunity - Part II: others
Inborn errors of immunity (IEI) are a large, heterogeneous group of disorders resulting from deficiencies in immune system development and/or function, leading to increased susceptibility to infections, autoimmunity, autoinflammation, lymphoproliferation, and malignancy. Some diseases are classical hematopoietic cell transplantation (HCT) indications, such as Wiskott-Aldrich Syndrome, but more than 150 different IEI have been transplanted. Each disease and patient should be addressed individually as the clinical manifestations are variable, as well as the pre- and post-transplant care. This consensus strongly recommends that these patients are referred to experienced centers performing HCT for IEI.
- 22 January 2025
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 6 (1)
Open AccessHematopoietic cell transplantation in inborn errors of immunity - Part II: others
Inborn errors of immunity (IEI) are a large, heterogeneous group of disorders resulting from deficiencies in immune system development and/or function, leading to increased susceptibility to infections, autoimmunity, autoinflammation, lymphoproliferation, and malignancy. Some diseases are classical hematopoietic cell transplantation (HCT) indications, such as Wiskott-Aldrich Syndrome, but more than 150 different IEI have been transplanted. Each disease and patient should be addressed individually as the clinical manifestations are variable, as well as the pre- and post-transplant care. This consensus strongly recommends that these patients are referred to experienced centers performing HCT for IEI.
- Open Access
- 22 January 2025
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 6 (1)
Hematopoietic cell transplantation in inborn errors of immunity Part I: severe combined immunodeficiency
Severe Combined Immunodeficiencies (SCID) are rare diseases characterized by a blockage in T-lymphocyte development. Hematopoietic Cell Transplantation (HCT) is the primary curative therapy, with the highest survival rates correlated to early diagnosis and the absence of active infections at transplant. The gold standard is a matched related sibling donor (MSD), but alternative donors like haploidentical family donors are increasingly used. Conditioning regimens vary, with reduced intensity busulfan and fludarabine often indicated. Early diagnosis via newborn screening and referral to experienced HCT centers are crucial for improving outcomes. Long-term follow-up is essential, as the cumulative incidence of late effects, such as neurologic and neurodevelopmental issues, increases over time.
- 22 January 2025
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 6 (1)
Open AccessHematopoietic cell transplantation in inborn errors of immunity Part I: severe combined immunodeficiency
Severe Combined Immunodeficiencies (SCID) are rare diseases characterized by a blockage in T-lymphocyte development. Hematopoietic Cell Transplantation (HCT) is the primary curative therapy, with the highest survival rates correlated to early diagnosis and the absence of active infections at transplant. The gold standard is a matched related sibling donor (MSD), but alternative donors like haploidentical family donors are increasingly used. Conditioning regimens vary, with reduced intensity busulfan and fludarabine often indicated. Early diagnosis via newborn screening and referral to experienced HCT centers are crucial for improving outcomes. Long-term follow-up is essential, as the cumulative incidence of late effects, such as neurologic and neurodevelopmental issues, increases over time.
- Open Access
- 22 January 2025
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 6 (1)
Acquired severe aplastic anemia
Acquired severe aplastic anemia is a rare, life-threatening condition characterized by pancytopenia and hypocellularity of the bone marrow. It shows a bimodal age distribution, with approximately 70–80% of cases classified as idiopathic. Recent advances in hematopoietic cell transplantation, immunosuppressive therapy, biological agents, and supportive care have greatly improved survival rates, reaching a 95% cure rate. Differential diagnoses include refractory cytopenia of childhood, inherited bone marrow failure syndromes, and other blood disorders. The aim of this article was to update the Brazilian consensus previously published by the Brazilian Society of Cellular Therapy and Bone Marrow Transplantation in 2021, highlighting the latest developments in the treatment and monitoring of severe aplastic anemia patients undergoing hematopoietic cell transplantation.
- 22 January 2025
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 6 (1)
Open AccessAcquired severe aplastic anemia
Acquired severe aplastic anemia is a rare, life-threatening condition characterized by pancytopenia and hypocellularity of the bone marrow. It shows a bimodal age distribution, with approximately 70–80% of cases classified as idiopathic. Recent advances in hematopoietic cell transplantation, immunosuppressive therapy, biological agents, and supportive care have greatly improved survival rates, reaching a 95% cure rate. Differential diagnoses include refractory cytopenia of childhood, inherited bone marrow failure syndromes, and other blood disorders. The aim of this article was to update the Brazilian consensus previously published by the Brazilian Society of Cellular Therapy and Bone Marrow Transplantation in 2021, highlighting the latest developments in the treatment and monitoring of severe aplastic anemia patients undergoing hematopoietic cell transplantation.
- Open Access
- 22 January 2025
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 6 (1)
Hematopoietic cell transplantation in inherited bone marrow failure syndromes
Inherited bone marrow failure syndromes (IBMFS) comprise a heterogeneous group of rare genetic disorders characterized by defective hematopoiesis, congenital anomalies, and a predisposition to clonal evolution and malignancies. Hematopoietic cell transplantation remains the only curative option for the hematologic manifestations of these disorders, although it does not correct congenital malformations or eliminate the long-term risk of non-hematopoietic cancers. This review summarized current evidence and transplantation strategies for major IBMFS, including Fanconi anemia, dyskeratosis congenita/telomere biology disorders, Diamond-Blackfan anemia, Shwachman-Diamond syndrome, congenital neutropenia, congenital amegakaryocytic thrombocytopenia, and other inherited thrombocytopenias. We discussed disease-specific transplant indications, donor selection, conditioning regimens, graft source preferences, and outcomes across different patient populations. Advances in reduced-intensity conditioning and post-transplant cyclophosphamide have expanded donor availability, improving survival even with alternative donors. Nevertheless, long-term challenges persist, such as increased risks of solid tumors, endocrine dysfunction, and organ toxicity, emphasizing the need for multidisciplinary care and lifelong surveillance. Optimal outcomes depend on timely referral to specialized centers, meticulous donor screening, and individualized transplant strategies tailored to the unique biology of each disorder.
- 22 January 2025
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 6 (1)
Open AccessHematopoietic cell transplantation in inherited bone marrow failure syndromes
Inherited bone marrow failure syndromes (IBMFS) comprise a heterogeneous group of rare genetic disorders characterized by defective hematopoiesis, congenital anomalies, and a predisposition to clonal evolution and malignancies. Hematopoietic cell transplantation remains the only curative option for the hematologic manifestations of these disorders, although it does not correct congenital malformations or eliminate the long-term risk of non-hematopoietic cancers. This review summarized current evidence and transplantation strategies for major IBMFS, including Fanconi anemia, dyskeratosis congenita/telomere biology disorders, Diamond-Blackfan anemia, Shwachman-Diamond syndrome, congenital neutropenia, congenital amegakaryocytic thrombocytopenia, and other inherited thrombocytopenias. We discussed disease-specific transplant indications, donor selection, conditioning regimens, graft source preferences, and outcomes across different patient populations. Advances in reduced-intensity conditioning and post-transplant cyclophosphamide have expanded donor availability, improving survival even with alternative donors. Nevertheless, long-term challenges persist, such as increased risks of solid tumors, endocrine dysfunction, and organ toxicity, emphasizing the need for multidisciplinary care and lifelong surveillance. Optimal outcomes depend on timely referral to specialized centers, meticulous donor screening, and individualized transplant strategies tailored to the unique biology of each disorder.
- 27 October 2024
- Published by Wiley in British Journal of Haematology
- Vol. 205 (6) , 2387-2402
Haematopoietic cell transplantation for 106 infants and preschoolers with acquired and inherited bone marrow failures
Summary: Aplastic anaemia in infants and young children presents unique challenges due to high prevalence of inherited bone marrow failure syndromes (IBMFS) in this age group. The objective of this study is assessing clinical characteristics and outcomes of haematopoietic cell transplantation in children ≤5 years with bone marrow failure syndromes. We analysied 106 patients (66% males), median age 4.6 years, including 40 with Fanconi anaemia (FA), 32 with Acquired Severe Aplastic anaemia (aSAA), 15 with Diamond–Blackfan Anaemia, 11 with Amegakaryocytic Purpura and 8 with other IBMFS. Molecular testing was limited (39%), with 25.4% confirmed genetically. Retrospective longitudinal study across three paediatric transplantation centres (1982–2020). Overall survival (OS) was 76.4% over a median 10‐year follow‐up. OS rates were similar between aSAA and IBMFS (FA 77.5%, other IBMFS 76.5%). Transplant‐related mortality (TRM) was lower in aSAA (9.4%) compared with IBMFS (16.2%). Recent years showed improved outcomes, with TRM declining post‐2010. Choice of stem cell source impacted OS, favouring bone marrow over umbilical cord, but showing encouraging results with haploidentical. Late complications were common, including endocrine‐metabolic issues and delayed neuropsychomotor development. Diagnosing and managing bone marrow failures in young children pose significant challenges. Despite advancements in transplant practices, ongoing vigilance and comprehensive care are necessary to improve long‐term survival rates.
- 27 October 2024
- Published by Wiley in British Journal of Haematology
- Vol. 205 (6) , 2387-2402
Haematopoietic cell transplantation for 106 infants and preschoolers with acquired and inherited bone marrow failures
Summary: Aplastic anaemia in infants and young children presents unique challenges due to high prevalence of inherited bone marrow failure syndromes (IBMFS) in this age group. The objective of this study is assessing clinical characteristics and outcomes of haematopoietic cell transplantation in children ≤5 years with bone marrow failure syndromes. We analysied 106 patients (66% males), median age 4.6 years, including 40 with Fanconi anaemia (FA), 32 with Acquired Severe Aplastic anaemia (aSAA), 15 with Diamond–Blackfan Anaemia, 11 with Amegakaryocytic Purpura and 8 with other IBMFS. Molecular testing was limited (39%), with 25.4% confirmed genetically. Retrospective longitudinal study across three paediatric transplantation centres (1982–2020). Overall survival (OS) was 76.4% over a median 10‐year follow‐up. OS rates were similar between aSAA and IBMFS (FA 77.5%, other IBMFS 76.5%). Transplant‐related mortality (TRM) was lower in aSAA (9.4%) compared with IBMFS (16.2%). Recent years showed improved outcomes, with TRM declining post‐2010. Choice of stem cell source impacted OS, favouring bone marrow over umbilical cord, but showing encouraging results with haploidentical. Late complications were common, including endocrine‐metabolic issues and delayed neuropsychomotor development. Diagnosing and managing bone marrow failures in young children pose significant challenges. Despite advancements in transplant practices, ongoing vigilance and comprehensive care are necessary to improve long‐term survival rates.
- 1 May 2024
- Published by Elsevier in Cytotherapy
- Vol. 26 (9) , 980-987
Immune recovery and the role of recent thymic emigrated T lymphocytes after pediatric hematopoietic stem cell transplantation
- 1 May 2024
- Published by Elsevier in Cytotherapy
- Vol. 26 (9) , 980-987
Immune recovery and the role of recent thymic emigrated T lymphocytes after pediatric hematopoietic stem cell transplantation
- Open Access
- 22 September 2022
- Published by Sociedade Brasileira de Pneumologia e Tisiologia in Jornal Brasileiro de Pneumologia
- Vol. 48 (5) , e20220134
Pulmonary complications after hematopoietic stem cell transplantation in children: a functional and tomographic evaluation
- 22 September 2022
- Published by Sociedade Brasileira de Pneumologia e Tisiologia in Jornal Brasileiro de Pneumologia
- Vol. 48 (5) , e20220134
Open AccessPulmonary complications after hematopoietic stem cell transplantation in children: a functional and tomographic evaluation
- 29 May 2022
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 44 (5) , 900-906
Somatic mosaicism in patients with Fanconi anaemia: Proposal of alternative tissue for inconclusive diagnoses
Introduction: Fanconi anaemia (FA) is a rare genetic disorder marked by progressive bone marrow failure, chromosomal fragility, and increased cancer susceptibility. Laboratory diagnosis includes chromosomal instability test and mutation investigation. A total of 15%–25% of all patients may have somatic mosaicism, characterized by two distinct haematopoietic cell populations, one resistant and one sensitive to agents that induce chromosomal breakage, which complicates the diagnosis by a high incidence of reverted cells leading to inconclusive or false‐negative results. The study aimed to evaluate the use of bone marrow stromal mesenchymal cells (BM‐MSCs) as an alternative, non‐haematopoietic tissue for diagnosis.Methods: Bone marrow mesenchymal stromal cells from 12 patients with positive diepoxybutane (DEB) tests were cultivated and analysed by cytogenetics and mutation investigation.Results: The DEB test was performed at 0.1 and 0.01 μg/ml concentrations, with an index ranging from 0.24 to 1.00. At higher concentration, the metaphases number was lower, probably due to toxicity. Regarding the molecular investigation, all the mutations previously found in peripheral blood were identified on BM‐MSC.Conclusion: This study demonstrated the possibility of using BM‐MSCs as an alternative tissue for cytogenetic and molecular investigation. Future tests using an intermediate DEB concentration may lead to an optimal protocol that could be non‐toxic to cells but provides conclusive results.
- 29 May 2022
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 44 (5) , 900-906
Somatic mosaicism in patients with Fanconi anaemia: Proposal of alternative tissue for inconclusive diagnoses
Introduction: Fanconi anaemia (FA) is a rare genetic disorder marked by progressive bone marrow failure, chromosomal fragility, and increased cancer susceptibility. Laboratory diagnosis includes chromosomal instability test and mutation investigation. A total of 15%–25% of all patients may have somatic mosaicism, characterized by two distinct haematopoietic cell populations, one resistant and one sensitive to agents that induce chromosomal breakage, which complicates the diagnosis by a high incidence of reverted cells leading to inconclusive or false‐negative results. The study aimed to evaluate the use of bone marrow stromal mesenchymal cells (BM‐MSCs) as an alternative, non‐haematopoietic tissue for diagnosis.Methods: Bone marrow mesenchymal stromal cells from 12 patients with positive diepoxybutane (DEB) tests were cultivated and analysed by cytogenetics and mutation investigation.Results: The DEB test was performed at 0.1 and 0.01 μg/ml concentrations, with an index ranging from 0.24 to 1.00. At higher concentration, the metaphases number was lower, probably due to toxicity. Regarding the molecular investigation, all the mutations previously found in peripheral blood were identified on BM‐MSC.Conclusion: This study demonstrated the possibility of using BM‐MSCs as an alternative tissue for cytogenetic and molecular investigation. Future tests using an intermediate DEB concentration may lead to an optimal protocol that could be non‐toxic to cells but provides conclusive results.
- Open Access
- 17 March 2022
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 28 (3) , S452-S453
Data Management Training Program of the First Brazilian Hematopoietic Stem Cell Transplant Center Affiliated to the CIBMTR
- 17 March 2022
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 28 (3) , S452-S453
Open AccessData Management Training Program of the First Brazilian Hematopoietic Stem Cell Transplant Center Affiliated to the CIBMTR
- Open Access
- 10 February 2022
- Published by Elsevier in The Brazilian Journal of Infectious Diseases
- Vol. 26, 102224
SURTO DE MUCORMICOSE CAUSADA POR RHIZOMUCOR PUSSILUS EM UMA UNIDADE DE TRANSPLANTE DE CÉLULAS TRONCO HEMATOPOIÉTICAS
- 10 February 2022
- Published by Elsevier in The Brazilian Journal of Infectious Diseases
- Vol. 26, 102224
Open AccessSURTO DE MUCORMICOSE CAUSADA POR RHIZOMUCOR PUSSILUS EM UMA UNIDADE DE TRANSPLANTE DE CÉLULAS TRONCO HEMATOPOIÉTICAS